versão impressa ISSN 0121-0793
Iatreia v.21 supl.1 Medellín mar. 2008
Chelating capacity and the adverse effects of two treatments (Nacetylcysteine and Dpenicillamine) in patients with mercury poisoning in Segovia, a municipality at the northeastern part of Antioquia, Colombia
Claudia Lucía Arroyave1, Carlos Federico Molina Castaño1, Ana María Suárez1, Natalia Maldonado1, Fanny Cuesta González1
- Departament of Pharmacology and Toxicology, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia.
Telefax: (574) 210 60 20. firstname.lastname@example.org
OBJECTIVE: to compare the chelating capacity and the adverse effects of treatments with either Nacetylcysteine or Dpenicillamine in patients with mercury poisoning in Segovia, a municipality at the northeastern part of Antioquia, Colombia.
METHODS: 50 patients with toxic levels of mercury were enrolled in a 10 days open label, randomized comparison of either Dpenicillamine (750 mg/day) or Nacetilcysteine (1.8 g/day). Patients were followed on a daily basis to assess the elimination of mercury in urine and the frequency of adverse effects of each treatment.
RESULTS: 32 patients completed 10 days of drug treatment. Averages of mercury elimination in 24 hours urine, before and after treatment with Dpenicillamine and Nacetylcysteine, were not different (211.96 mcg ± 190 and 262.15 mcg ± 305 and 232.85 mcg ± 248 and 218.65 mcg ± 240, respectively, P > 0.05 for all comparisons). Evaluation of the frequency of adverse effects showed a significant difference between the two groups: Dpenicillamine (50%) and Nacetylcysteine (11%) p = 0.0079.
CONCLUSION: this study did not reveal any significant differences between the chelating capacity of Dpenicillamine and Nacetylcysteine in patients with mercury poisoning, from a mining population at the northeastern part of Antioquia, Colombia. However, there were significantly less adverse effects with the Nacetylcysteine treatment.